Patent ID: 7186514
Filing Date: 2007-03-06
Classification: A61K,A61P,C07K,C12N

Abstract:
1. A method of screening for preneoplastic/neoplastic disease associated with abnormal MN gene expression comprising: (a) determining whether abnormal MN gene expression is present in a human using a polymerase chain reaction based assay on a sample from said human; and (b) if abnormal MN gene expression is determined to be present in said human, determining that said human has a significant risk of having preneoplastic/neoplastic disease; wherein said MN gene encodes an MN protein that is encoded by a nucleic acid having a nucleotide sequence selected from the group consisting of: (1) SEQ ID NO: 1; (2) nucleotide sequences that hybridize under stringent conditions to complement of SEQ ID NO: 1; and (3) nucleotide sequences that differ from SEQ ID NO: 1 or from the nucleotide sequences of (2) in codon sequence due to the degeneracy of the genetic code; and wherein abnormal MN gene expression is detected by: (c1) preparing cDNA from MN mRNA present in said human sample; (c2) amplifying any said cDNA; and (c3) detecting the presence of any resulting amplified DNA, or quantitating any resulting amplified DNA, wherein the presence of such amplified DNA or an abnormal level of said amplified DNA indicates the presence of preneoplastic/neoplastic disease in said human.